​

Low-Dose Naltrexone (LDN) Primer — Key Takeaways

Purpose:
This primer provides a practical, experience-based framework for optimizing LDN therapy, recognizing that ~30–40% of patients do not respond to standard protocols and require individualized strategies.

​

LDN Effectiveness & Response Spectrum

• Published response rates in chronic pain populations: ~57–65%

• Patients fall into three response categories:

1. LDN as Sufficient Therapy

   • LDN alone produces sustained benefit

   • Typical features: adequate endorphin reserve, moderate disease severity, neuroinflammatory or immune-driven conditions

   • Strong evidence in fibromyalgia and chronic pain

2. LDN as Necessary but Not Sufficient

   • LDN is helpful but must be combined with other therapies

   • Seen in complex illnesses: MCAS, Long COVID, CIRS, cancer, CRPS, chronic Lyme

   • LDN helps calm immune dysregulation, improving tolerance of deeper treatments

3. Non-Responders

   • No benefit at any dose

   • Possible reasons: severely depleted endorphins, genetic opioid receptor differences, or disease mechanisms outside LDN’s pathways

   • ​

Core Clinical Concept: Endorphin Reserve

• Treatment success depends heavily on baseline functional capacity, not diagnosis alone

• Indicators include:

  • Duration of illness

  • Sleep quality

  • Energy levels

  • Resilience to stress

  • Ability to function daily

• Severely depleted patients often cannot tolerate standard 1.5–4.5 mg dosing

​

Dosing Strategies

LDN Research Trust dose categories:

• Ultra-low dose: 1–2 micrograms

• Very-low dose: 0.01–0.5 mg

• Low dose: 1–4.5 mg (sometimes up to 10 mg)

Key principles:

• Start much lower in severely ill, sensitive, or pediatric patients

• Microgram dosing may act via hormesis rather than opioid blockade

• Some patients require nanogram dosing via dilution when extremely sensitive

• Slow titration is essential:

  • Dose increases every 2 weeks, 4 weeks, or even every 1–3 months in sensitive patients

​

When Standard LDN Fails: Advanced Strategies

1. Neuropathic Pain

   • Consider higher-dose naltrexone (25–45 mg)

   • Combine with nutritional ketosis

   • Mechanism may differ from classic LDN

2. MCAS & Complex Immune Disorders

   • Add:

     • Ketotifen (mast cell stabilizer)

     • Cromolyn sodium

     • Methylene blue + ketosis for mitochondrial and neuroinflammatory support

​

Practical Clinical Guidance

• Moderate illness: start 1.5 mg → titrate to 4.5 mg

• Severely ill: start ≤0.5 mg with slow escalation

• Children: microgram dosing

• Extreme sensitivity: nanogram ranges

• Side effects: reduce dose and slow titration

• Refractory cases: comprehensive functional medicine evaluation

• ​

Bottom Line

• LDN is powerful but not universal

• Failure of standard dosing does not equal failure of LDN

• Outcomes improve with:

  • Assessment of endorphin reserve

  • Flexible dosing strategies

  • Integration with metabolic, immune, and mitochondrial therapies

• Individualization is the cornerstone of successful LDN treatment

​

​​​

​